Merck's Q4 earnings call revealed a mixed bag, with strong revenue performance and significant cost reductions, but also tempered guidance and uncertainties around key products like vorapaxar. The company's decision to withdraw its 2013 EPS target and invest in growth initiatives may lead to short-term pressure on the stock. However, management's focus on innovation, emerging markets, and cost-cutting measures suggests a potential for long-term growth.

[1]